Skip to main content

Table 2 Unadjusted biomarker concentrations at study baseline and follow up time points

From: Biomarker profiling for risk of future heart failure (HFpEF) development

Biomarker HFpEF progressor HFpEF Non progressor p-value
BNP Baseline 107.7 [51.4:179.2] 39.8 [19.6:74.5]  < 0.001
BNP Follow up 117.0 [63.9:179.0] 47.2 [25.4:79.1]  < 0.001
Galecin-3 Baseline 15.9 [14.8:18.6] 14.9 [12.5:18.3] 0.0663
Galectin-3 Follow up 17.9 [14.8:20.0] 15.4 [12.5:18.0] 0.0090
hsTroponin I Baseline 7.7 [5.6:10.0] 5.8 [4.8:7.7] 0.0647
hsTroponin I Follow up 7.2 [5.8:10.9] 6.2 [4.5:7.6] 0.0202
sST2 Baseline 25.3 [21.3:30.5] 22.9 [20.5:29.0] 0.3711
sST2 Follow up 25.3 [22.6:29.8] 24.6 [19.6:32.3] 0.4488
IL6 Baseline 1.4 [1.0:2.1] 1.1 [0.76:1.8] 0.0731
IL6 Follow up 1.4 [1.0:1.8] 1.0 [0.79:1.9] 0.0861
  1. BNP b-type natriuretic peptide, hsTroponin I high sensitivity troponin I, sST2 soluble suppression of tumorigenicity 2, IL6 interleukin 6. Units, BNP pg/mL; Galectin-3 ng/mL; hsTroponin I pg/mL; sST2 ng/mL; IL6 pg/mL